A NEW STANDARD OF CARE
Fifty percent of patient tumors are categorized grade 2, forcing oncologists to rely on further testing. But large percentages of patients with grade 2 and 3 tumors are eventually discovered to be low risk of recurrence and could have been spared the time and costs of gene expression testing.
LEARN MORE, FASTER.
PreciseBreast™ offers a faster, less expensive alternative to gene expression testing for predicting the risk of recurrence with equivalent accuracy. ¹
1. Mahtani, R. L. 2024. PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospectivestudy of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc. [Poster]. SABCS, Dec. 9, 2024, San Antonio, TX.
Traditional tumor grading in breast cancer can be subjective, resulting in a high percentage of patients being classified with Intermediate/Grade 2 tumors even though many are low risk. As a result, patients must wait 2-6 weeks for costly gene expression test results, ultimately delaying vital care planning.
65%
Intra-observer variations in grading results***
56%
of Grade 3 tumors are low risk**
22%
of Grade 2 tumors are high risk**
78%
of Grade 2 tumors are low risk**
*Sparano, New England Journal of Medicine. 2018
**Based on a retrospective longitudinal study of more than 2,000 cancer cases. Fernandez, G., Prastawa, M., Madduri, A.S. et al. Breast Cancer Research 2022’.
***Paik, New England Journal of Medicine, 2004
Using PreciseBreastTM as well as gene expression or visual pathologic analysis delivers benefits for patients, physicians, and payors.
.svg)
Data to drive precise reporting of tumor recurrence risk
Faster results lessen anxiety for patients
.svg)
Lower overall costs for treatment and testing
Availability to 100% of eligible patients
our process
PreciseBreast is designed specifically to improve the multidisciplinary team’s workflow, providing a complement to pathological tumor grading and gene expression testing.
Screening / Detection
Biopsy & Diagnosis
Resection
Tumor Grading
Tumor Staging
Gene-Expression Testing
Care Planning
The results of slow or unavailable gene-expression testing can impact patients and their anxiety levels during a critical time in their lives. These are their stories of how PreciseBreast might have made a difference.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here
Contact us today to learn more about PreciseBreast.
